<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01400750</url>
  </required_header>
  <id_info>
    <org_study_id>MP1</org_study_id>
    <nct_id>NCT01400750</nct_id>
  </id_info>
  <brief_title>Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis</brief_title>
  <acronym>CCTOBI</acronym>
  <official_title>Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of new Pseudomonas aeruginosa (Pa) infection in cystic fibrosis (CF) can postpone
      chronic infection. Aim of the study: compare 2 Pa eradication regimens in children with new
      Pa infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: CF children (0-18 years) with a new isolation of Pa from the airway were randomized
      to tobramycin inhalation solution (TOBI® 2x300 mg for 28 days) (TIS) or inhaled
      colistimethate sodium (Colistineb® 2x2 mill U daily) plus oral ciprofloxacin (30mg/kg/day)
      for 3 months (CC). The primary outcome was eradication at end of treatment. Secondary outcome
      parameters were time to Pa relapse, total and Pa specific IgG, FEV1, BMI and Pa status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pseudomonas aeruginosa eradication at the end of the treatment.</measure>
    <time_frame>end of study drug treatment ie 3 months for CC and at 1 months for TIS</time_frame>
    <description>sucessful eradication is defined as negative airway culture for P aeruginosa and end of study drug which is after 3 months for ciproxin-colistin (CC) and after 1 months for tobramycin for inhalation (TIS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>P aeruginosa eradication at 6 months after study entry</measure>
    <time_frame>6 months</time_frame>
    <description>negative airway cultures for P aeruginosa up to 6 months after start of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to new Pa positive culture (= relapse)</measure>
    <time_frame>1 year</time_frame>
    <description>Time to first new P aeruginosa positive airway culture (expressed in months starting from end of study drug)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline FEV1% pred, IgG z score, BMI z score was followed</measure>
    <time_frame>1 year</time_frame>
    <description>Evolution of lung function (expressed as FEV1% pred), total IgG and nutritional status (expressed as BMI z score) from start of study up to 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titer for specific anti Pseudomonas antibodies</measure>
    <time_frame>1 year</time_frame>
    <description>Pa antibodies (ELISA St Ag 1-17 )were measured at baseline and at 1 year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P aeruginosa infection status</measure>
    <time_frame>1 year</time_frame>
    <description>P aeruginosa infection status was reported as 'Free off', 'Intermittent' or 'Chronic' according to the Leeds criteria after 1 and 2 years.
(ref Leeds criteria: Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003;2(1):29-34)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P aeruginosa infection status</measure>
    <time_frame>2 years</time_frame>
    <description>P aeruginosa infection status was reported as 'Free off', 'Intermittent' or 'Chronic' according to the Leeds criteria after 1 and 2 years.
(ref Leeds criteria: Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003;2(1):29-34)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Ciproxin-inhaled Colistin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral ciprofloxacin (30mg/kg/day) plus inhaled colistimethate sodium (Colistineb® 2x2 mill U daily) for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobramycine for inhalation (TIS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral ciprofloxacin plus inhaled colistin</intervention_name>
    <description>oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)</description>
    <arm_group_label>Ciproxin-inhaled Colistin</arm_group_label>
    <other_name>Ciproxin ® - ciprofloxacin</other_name>
    <other_name>Colistineb ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOBI</intervention_name>
    <description>tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days</description>
    <arm_group_label>Tobramycine for inhalation (TIS)</arm_group_label>
    <other_name>TOBI® - tobramycin inhalation solution (TIS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of CF (clinical signs consistent with CF and a sweat chloride &gt; 60 mEq/l by
             quantitative pilocarpine iontophoresis and/or two CF causing mutations identified)

          -  age 0 to 18 years old at time of inclusion

          -  'First' or 'new Pa infection' defined as 'first Pa isolation ever' or 'isolation of Pa
             from the airway (sputum, throat swab or BAL) after a Pa free interval of at least 6
             months and documented with at least 3 negative cultures'.

        Exclusion Criteria:

          -  chronic Pa infection defined according to the Leeds criteria[17]

          -  pulmonary exacerbation needing IV AB treatment at time of new Pa isolate

          -  Pa isolation at time of CF diagnosis

          -  patient already on an antipseudomonal antibiotic

          -  interval between positive culture and start of treatment &gt; 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marijke J Proesmans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep pediatrics University Hospital Leuven Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of pediatrics, CF center Uuiversity Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <results_reference>
    <citation>Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004197. doi: 10.1002/14651858.CD004197.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;11:CD004197.</citation>
    <PMID>19821321</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof M Proesmans</name_title>
    <organization>University Hospital Leuven, dep of pediatrics</organization>
  </responsible_party>
  <keyword>cystic fibrosis- P aeruginosa- eradication-child</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

